Japanese Surveillance Systems and Treatment for Influenza
暂无分享,去创建一个
[1] Alicia M Fry,et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. , 2014, The Lancet. Infectious diseases.
[2] A. Hurt,et al. A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade , 2014, Scientifica.
[3] Shinji Watanabe,et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[4] J. Weitkamp,et al. Influenza A virus-associated acute necrotizing encephalopathy in the United States. , 2004, The Pediatric infectious disease journal.
[5] D. Smee,et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. , 2013, Antiviral research.
[6] R. Saito,et al. Influenza Virus Shedding in Laninamivir-Treated Children upon Returning to School. , 2016, The Tohoku journal of experimental medicine.
[7] S. Günther,et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. , 2014, Antiviral research.
[8] N. Okabe,et al. Prognostic Factors in Influenza-associated Encephalopathy , 2008, The Pediatric infectious disease journal.
[9] Jo Leonardi-Bee,et al. Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009–2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients , 2012, The Journal of infectious diseases.
[10] S. Kashiwagi,et al. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010–2011 season: comparison with the previous season and with seasonal A(H3N2) and B , 2012, Influenza and other respiratory viruses.
[11] J. Nguyen-Van-Tam,et al. Neuraminidase inhibitors: who, when, where? , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[12] A. Borobia,et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. , 2015, The Lancet. Respiratory medicine.
[13] S. Kashiwagi,et al. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] Takao Takahashi,et al. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. , 2011, The Journal of infection.
[15] Yuji Takemoto,et al. Clinical Effects of Oseltamivir, Zanamivir, Laninamivir and Peramivir on Seasonal Influenza Infection in Outpatients in Japan during the Winter of 2012-2013 , 2014, Chemotherapy.
[16] Takao Takahashi,et al. Effectiveness of Trivalent Inactivated Influenza Vaccine in Children Estimated by a Test-Negative Case-Control Design Study Based on Influenza Rapid Diagnostic Test Results , 2015, PloS one.
[17] H. Sakata,et al. JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy – The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG , 2016, Journal of Infection and Chemotherapy.
[18] J. McKimm-Breschkin,et al. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses , 2016, Antiviral Research.
[19] A. Hurt. The epidemiology and spread of drug resistant human influenza viruses. , 2014, Current opinion in virology.
[20] Estimated Number of Patients with Influenza A(H1)pdm09, or Other Viral Types, from 2010 to 2014 in Japan , 2016, PloS one.
[21] S. Kashiwagi,et al. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[22] T. Kanda,et al. Effects of Vaccination and the New Neuraminidase Inhibitor, Laninamivir, on Influenza Infection , 2014, PloS one.
[23] M. Mizuguchi,et al. Phase III Randomized, Double-Blind Study Comparing Single-Dose Intravenous Peramivir with Oral Oseltamivir in Patients with Seasonal Influenza Virus Infection , 2011, Antimicrobial Agents and Chemotherapy.
[24] M. Mizuguchi. Influenza encephalopathy and related neuropsychiatric syndromes , 2013, Influenza and other respiratory viruses.
[25] M. Peiris,et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance , 2013, The Lancet.
[26] R. Saito,et al. Genetic Characterization of Human Influenza Viruses in the Pandemic (2009–2010) and Post-Pandemic (2010–2011) Periods in Japan , 2012, PloS one.
[27] Y. Ota,et al. Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan , 2015, The clinical respiratory journal.
[28] S. Fujimoto,et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis , 1998, The Lancet.
[29] Takao Takahashi,et al. Efficacy, Safety, and Pharmacokinetics of Intravenous Peramivir in Children with 2009 Pandemic H1N1 Influenza A Virus Infection , 2011, Antimicrobial Agents and Chemotherapy.
[30] A. Moscona. Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.
[31] K. Ohe,et al. Evaluation of two Japanese regulatory actions using medical information databases: a ‘Dear Doctor’ letter to restrict oseltamivir use in teenagers, and label change caution against co‐administration of omeprazole with clopidogrel , 2014, Journal of clinical pharmacy and therapeutics.
[32] N. Okabe,et al. Influenza surveillance system of Japan and acute encephalitis and encephalopathy in the influenza season , 2000, Pediatrics international : official journal of the Japan Pediatric Society.
[33] S. Choi,et al. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza , 2015, Journal of medical virology.
[34] F Y Aoki,et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. , 2003, The Journal of antimicrobial chemotherapy.
[35] T. Kamigaki,et al. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan , 2009, PLoS currents.
[36] P. Penttinen,et al. ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation , 2016, Influenza and other respiratory viruses.
[37] M. Mizuguchi,et al. Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus Infection , 2010, Antimicrobial Agents and Chemotherapy.
[38] Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. , 2016, Releve epidemiologique hebdomadaire.
[39] G. Neumann,et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. , 2016, Antiviral research.
[40] Y. Ohkusa,et al. Abnormal behavior during influenza in Japan during the last seven seasons: 2006-2007 to 2012-2013. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[41] Kazuhito Shiosakai,et al. Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[42] A. Sutton,et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials , 2003, BMJ : British Medical Journal.
[43] Y. Ohashi,et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] K. Hashimoto,et al. Life-Threatening Abnormal Behavior Incidence in 10–19 Year Old Patients Administered Neuraminidase Inhibitors , 2015, PloS one.
[45] M. Mizuguchi,et al. Intravenous Peramivir for Treatment of Influenza A and B Virus Infection in High-Risk Patients , 2011, Antimicrobial Agents and Chemotherapy.
[46] M. Hosoya,et al. Influenza Viral Load and Peramivir Kinetics after Single Administration and Proposal of Regimens for Peramivir Administration against Resistant Variants , 2014, Antimicrobial Agents and Chemotherapy.
[47] M. Tashiro,et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] Larisa V. Gubareva,et al. Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.
[49] P. Ward,et al. Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.
[50] E F Mitchel,et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. , 2000, The New England journal of medicine.
[51] M. Ison,et al. Peramivir: an intravenous neuraminidase inhibitor , 2015, Expert opinion on pharmacotherapy.
[52] Avinash K. Shetty,et al. Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] M. Kakehashi,et al. Substantial Impact of School Closure on the Transmission Dynamics during the Pandemic Flu H1N1-2009 in Oita, Japan , 2015, PloS one.
[54] In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus , 2014, Archives of Virology.
[55] H. Zaraket,et al. Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections , 2016, Front. Microbiol..
[56] A. Lefor,et al. Favipiravir: A New Medication for the Ebola Virus Disease Pandemic , 2014, Disaster Medicine and Public Health Preparedness.
[57] Y. Kawaoka,et al. Comparison between virus Shedding and Fever Duration after Treating Children with Pandemic a H1N1/09 and Children with a H3N2 with a Neuraminidase Inhibitor , 2015, Antiviral therapy.
[58] K. Yoshihara,et al. Clinical Pharmacokinetics of Laninamivir, a Novel Long‐Acting Neuraminidase Inhibitor, After Single and Multiple Inhaled Doses of Its Prodrug, CS‐8958, in Healthy Male Volunteers , 2010, Journal of clinical pharmacology.
[59] T. Morishima,et al. National survey of pandemic influenza A (H1N1) 2009‐associated encephalopathy in Japanese children , 2012, Journal of medical virology.
[60] Yuuki Nakamura,et al. Evaluation of estimated number of influenza patients from national sentinel surveillance using the national database of electronic medical claims. , 2015, Japanese journal of infectious diseases.
[61] F. Kakuya,et al. Clinical findings in 10 children with H275Y influenza A(H1N1)pdm09 virus infection , 2015, Pediatrics international : official journal of the Japan Pediatric Society.
[62] E. Cox,et al. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. , 2009, The New England journal of medicine.
[63] N. Sugaya. Widespread use of neuraminidase inhibitors in Japan , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[64] J. Tang,et al. Full Genome Characterization of Human Influenza A/H3N2 Isolates from Asian Countries Reveals a Rare Amantadine Resistance-Conferring Mutation and Novel PB1-F2 Polymorphisms , 2016, Front. Microbiol..
[65] Yoshihiro Kawaoka,et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses , 2009, Proceedings of the National Academy of Sciences.
[66] M. Kondo. A bad dose of the 'flu , 2003, The Lancet.
[67] K. Taniguchi,et al. Description of hospitalized cases of influenza A(H1N1)pdm09 infection on the basis of the national hospitalized-case surveillance, 2009-2010, Japan. , 2015, Japanese journal of infectious diseases.
[68] J. McKimm-Breschkin,et al. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance , 2013, Influenza and other respiratory viruses.
[69] Yoshiaki Gu,et al. National Surveillance of Influenza-Associated Encephalopathy in Japan over Six Years, before and during the 2009–2010 Influenza Pandemic , 2013, PloS one.
[70] S. Kashiwagi,et al. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.